Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Roche. (6/5/17). "Press Release: APHINITY Study Shows Roche’s Perjeta-based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-positive Early Breast Cancer". Basel.

Organisations Organisation Roche (Group)
  Organisation 2 Breast International Group (BIG)
Products Product Perjeta™
  Product 2 clinical research
Person Person Horning, Sandra (Roche 201403 CMO + Head Global Product Development)

Record changed: 2017-06-16


Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Roche (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px

» top